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IgG immune complexes may contribute to neutrophil activation in the course of severe COVID-19 
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Less summary 
A role for immune complexes in the activation of neutrophils in severe COVID-19 is 
suggested by the association of circulating neutrophils with immune complexes and the 





















Severe COVID-19 is associated with an overactive inflammatory response mediated by 
macrophages. Here, we analyzed the phenotype and function of neutrophils in COVID-19 
patients. We found that neutrophils from severe COVID-19 patients express high levels of 
CD11b and CD66b, spontaneously produce CXCL8 and CCL2 and show a strong association 
with platelets. Production of CXCL8 correlated with plasmatic concentrations of LDH and D-
dimer. Whole blood assays revealed that neutrophils from severe COVID-19 patients show a 
clear association with IgG immune complexes. Moreover, we found that sera from severe 
patients contain high levels of immune complexes and activate neutrophils through a 
mechanism partially dependent on FcγRII (CD32). Interestingly, when integrated in immune 
complexes, anti-SARS-CoV-2 IgG antibodies from severe patients displayed a higher pro-
inflammatory profile compared with antibodies from mild patients. Our study suggests that 
IgG immune complexes might promote the acquisition of an inflammatory signature by 
neutrophils worsening the course of COVID-19. 
 





















SARS-CoV-2 infection induces a wide spectrum of clinical manifestations ranging from 
asymptomatic to severe disease and death [1]. Disease severity is associated to the induction 
of a systemic inflammatory response revealed by the high levels of inflammatory cytokines, 
chemokines and inflammatory markers such as C-reactive protein (CRP), ferritin, D-dimer, 
and LDH found in patients with severe COVID-19 [2]. Aberrant immune response in the lung 
is associated not only with severe COVID-19 but also with a variety of respiratory viral 
infections including those mediated by respiratory syncytial virus (RSV) and influenza A 
virus (IAV) [3, 4]. Neutrophils are the predominant cell type infiltrating the lung during 
severe RSV infection, and it has been demonstrated that they do not only promote epithelial 
cell damage and mucus overproduction but also enhance susceptibility to RSV infection [4, 
5].  Regarding IAV infection, it has been shown that patients with severe disease show a 
massive infiltration of the airway by neutrophils and an excessive production of neutrophil 
extracellular traps (NETs) being both responses associated with fatal outcome in 
experimental models and humans [6]. 
 
Macrophages are the major source of inflammatory cytokines in the course of severe 
COVID-19 [7]. By contrast, the contribution of neutrophils is not well defined. While 
contradictory reports have been published regarding the degree of airway infiltration by 
neutrophils in severe COVID-19 [8, 9], a large body of evidence suggest that neutrophils 
actually play a major role in the pathogenesis of severe COVID-19 [10,11]. Here, we show 
that neutrophils from severe COVID-19 patients display an activated phenotype, 
spontaneously produce CXCL8, and show a strong association with platelets. Moreover, our 
results suggest that IgG immune complexes (ICs) might contribute to the acquisition of an 





















Our study was approved by the Ethics Committees of the “Hospital de Clínicas José San 
Martín” and “Hospital Fernández” (Argentina), in accordance with the Declaration of 




Healthy individuals (n=42) were recruited from the blood bank of the “Hospital de Clínicas 
José San Martín”: age range 23-65 years, male 62%. COVID-19 patients (n=67) were 
recruited from the “Hospital de Clínicas José San Martín” and the “Hospital Fernández”. All 
COVID-19 patients were diagnosed by PCR amplification of SARS-CoV-2 viral RNA 
obtained from nasopharyngeal or oropharyngeal swabs. Taking into account the World 
Health Organization´s (WHO) eight-point scale for COVID-19 trial endpoints, patients were 
classified into three stages, i.e., mild, moderate, and severe [12]. Mild COVID-19 patients 
(WHO scores 1-2) were ambulatory patients or patients hospitalized with the aim of keeping 
them isolated; moderate patients (scores 3-4) included those with little or no requirement for 
supplemental oxygen; and severe patients included those with high-flow oxygen requirement 
(score 5), intubation and mechanical ventilation (score 6), and multi-organ support (score 7). 




















Isolation of Neutrophils and Monocytes  
Neutrophils were isolated from heparinized blood samples by centrifugation on Ficoll-Paque 
(GE Healthcare, Argentine) and dextran (Sigma-Aldrich) sedimentation. Contaminating 
erythrocytes were removed by hypotonic lysis. After washing, the cell pellets (>98% of 
neutrophils on May-Grunwald-Giemsa-stained cytopreparations) were suspended in RPMI-
1640 medium (Gibco Invitrogen, CA, USA). Neutrophils purity was confirmed by flow 
cytometry considering the forward (FSC) and side scatter (SSC) neutrophil properties, the 
high expression of CD66b, and the very low expression of CD14 that allows to distinguish 
neutrophils from monocytes. Peripheral blood mononuclear cells were isolated from the 
Ficoll-Paque gradient and monocytes were purified by positive selection using anti-CD14-
coated magnetic beads (Miltenyi Biotec, CA, USA) (% purity 89-97%). 
 
Analysis of Neutrophil Phenotype 
Labeled monoclonal antibodies (mAbs) directed to CD11b, CD14, CD41, CD66b, CD62L 
(L-selectin), CXCR1, CD62P (P-selectin), IgG, and isotype controls were from BD 
Biosciences (CA, USA). Data were acquired using a BD FACSCanto cytometer and BD 
FACSDiva software (BD Biosciences). Statistical analyses were based on at least 20000 
events gated in the neutrophil gate, defined as described above.  
 
Association of Platelets with Neutrophils 
It was studied by flow cytometry in whole blood samples by analyzing the platelet markers P-
selectin (CD62P) or CD41 in the neutrophil gate. Briefly, whole blood samples were 
collected by venipuncture into vacutainer heparin tubes and stained less than 30 min after 



















Neutrophil Transmigration Assay 
It was carried out using a Corning HTS Transwell 96 permeable supports (5 M pore size) 
(Corning, NY, USA). Unstimulated neutrophils (10 × 10
6
/ml) from healthy donors (HD) or 
severe COVID-19 patients were cultured at 37°C for 18 h, and supernatants were collected. 
Healthy neutrophils (1.5x10
5
/100 l) were added to the upper reservoir and neutrophil 
supernatants (100 l), IL-8 (10 ng/ml) or culture medium (control) were added to the lower 
reservoir. After 1 h at 37°C, neutrophils in the upper and lower chamber were quantified by 
flow cytometry, and the percentage of neutrophils that have migrated was determined. 
 
Association of IgG Antibodies with Neutrophils 
It was analyzed by flow cytometry in whole blood samples or isolated neutrophils. Whole 
blood assays were performed by analyzing the presence of IgG antibodies associated to the 
neutrophil surface in freshly heparinized blood samples previously washed five times with 
culture medium. Cells were stained with a FITC-labeled mAb directed to IgG, and samples 
were treated with BD FACS™ lysing solution prior to acquisition. Assays with isolated 
healthy neutrophils were performed by incubating neutrophils with serum (10%) from HD or 
COVID-19 patients for 1 h at 4°C. Experiments were performed at 4°C to avoid the 
internalization of IgG antibodies attached to the neutrophils surface. Then, cells were washed 
and IgG binding was revealed by staining with a labeled mAb directed to IgG.  
 
Estimation of circulating ICs 
It was performed by polyethyleneglycol (PEG) precipitation [13]. Briefly, 0.2 ml of serum 
was mixed with 0.4 ml of 0.01 M-borate buffer, pH 8.4. Then, 5.4 of 4.16% PEG 6000 was 
added (final serum dilution 1/30), and the mixture was incubated at room temperature for 60 


















serum that contains 1:30 diluted serum in borate buffer without PEG. Levels of ICs was 
expressed as PEG index = OD450 with PEG - OD450 without PEG x 1000. 
 
Quantitation of Neutrophil Apoptosis by Annexin-V Binding and Flow Cytometry 
Neutrophils (2x10
6
/ml) were cultured for 10 h at 37°C in RPMI medium supplemented with 
10% FCS, and annexin-V binding to apoptotic neutrophils was carried out using an apoptosis 
detection kit (BD Biosciences).  
 
Flow Cytometric Determination of Hydrogen Peroxide Production by Neutrophils 
It was evaluated by using the indicator dye dihydrorhodamine-123 (Molecular Probes, CA, 
USA) by flow cytometry. Neutrophils (2×10
6
/ml) were labeled with dihydrorhodamine-123 
and cultured for 30 min at 37°C without stimuli or in the presence of serum (10%) from HD 
or COVID-19 patients. In some experiments, neutrophils were pre-treated with a blocking 
antibody directed to FcγRII (clone IV.3, STEMCELL, FL, USA).  
 
Measurement of Cytokines by ELISA 
The presence of CXCL8, CCL2, TNF-α and IL6 in cell supernatants was analyzed by ELISA 
(Biolegend, CA, USA).  
 
Determination of Serum Titers of IgG Antibodies Against SARS-CoV-2 
It was performed by ELISA using the “COVIDAR IgG” kit (Laboratorio Lemos SRL, 
Buenos Aires, Argentina) that detects IgG antibodies against two viral antigens, trimeric 



















Activation of Neutrophils and Monocytes by Immune Complexes Prepared with Serum 
from Severe or Mild COVID-19 Patients 
We screen a large number of sera from COVID-19 patients by ELISA (COVIDAR IgG) and 
selected a panel of sera with high-titers (1:3200) of anti-SARS-CoV-2 IgG antibodies from 
severe or mild patients, that were used to prepare ICs and stimulate healthy neutrophils and 
monocytes. The titers of all sera were normalized to 1:3200. Then, sera from severe and mild 
patients were incubated for 1 h at room temperature in the plate of COVIDAR IgG kit, that 
contains two immobilized antigens of SARS-CoV-2, the trimeric spike protein and the RBD 





monocytes  suspended in 100 l of culture medium supplemented with 10% FCS 
were added. Release of hydrogen peroxide, expression of CD11b and production of cytokines 
were analyzed.    
 
Statistical Analysis 
When two groups were present, normally-distributed data were analyzed by two-sided t test 
and skewed data were analyzed by Mann–Whitney test or Wilcoxon test. For three or more 
groups, analysis was by one-way ANOVA or Kruskal–Wallis test with correction for 
multiple comparisons. Normality was assessed by Shapiro–Wilk test. Correlations were 
tested by Spearman’s method. Data analysis was done with GraphPad Prism software version 


















RESULTS   
All patients were diagnosed with COVID-19 by PCR amplification of SARS-CoV-2 viral 
RNA obtained from nasopharyngeal or oropharyngeal swabs. Patients were classified as 
mild, moderate or severe as described in Methods. Neutrophil activation is associated with 
phenotype changes such as the up-regulation of CD11b and CD66b, and L-selectin loss. We 
found that neutrophils isolated from severe COVID-19 patients, but not from patients with 
mild or moderate disease, showed a higher expression of CD11b and CD66b compared with 
HD (Figure 1A). A lower expression of L-selectin was also observed in severe patients, 
although it did not reach statistical significance when compared with HD (Figure 1B). 
Considering previous studies showing that the interaction with platelets promotes neutrophils 
activation [15, 16], we analyzed whether neutrophils from COVID-19 patients showed a 
greater tendency to interact with platelets. It was analyzed by flow cytometry in whole blood 
samples by studying the presence of the platelet markers P-selectin (CD62P) or CD41 in the 
neutrophil gate. Neutrophils from severe COVID-19 patients showed a higher association 
with platelets compared with healthy donors (Figure 1C). Moreover, a positive correlation 
was found between the degree of neutrophil-platelet association and the days of 
hospitalization (Figure 1C, right panel). No differences in the rate of apoptosis was 
observed for neutrophils isolated from patients or HD (Figure 1D).  
 
High serum IL6, CXCL8 and TNF-α levels at the time of hospitalization are predictors of 
COVID-19 patient survival [17]. We evaluated the spontaneous production of IL6, TNF-α 
and CXCL8 by neutrophils isolated from COVID-19 patients. No production of IL6 and 
TNF-α was observed (not shown). By contrast, neutrophils from severe COVID-19 patients 
spontaneously produced CXCL8 (Figure 2A, left). This production  correlated with two 


















(Figures 2A)  [2, 18]. Consistent with the ability of CXCL8 to induce the internalization of 
the CXCL8 receptor CXCR1 [19], neutrophils from severe COVID-19 patients showed a 
lower expression of CXCR1 compared with HD (Figure 2B). A higher spontaneous 
production of the chemokine CCL2 by isolated neutrophils from severe COVID-19 patients 
was also observed although it did not reach statistical significance when compared with HD 
(Figure 2C). Moreover, we found that neutrophil supernatants from severe COVID-19 
patients induced a strong chemotactic response on healthy neutrophils (Figure 2D).  
 
Considering that severe disease is associated not only with the production of high levels of 
anti-SARS CoV-2 IgG antibodies but also with the production of IgG autoantibodies [20-22], 
we analyzed the role of IgG antibodies and immune complexes (ICs) in neutrophil activation. 
Interestingly, flow cytometer analysis performed in whole blood samples revealed high levels 
of neutrophil-associated IgG antibodies in severe COVID-19 patients (Figure 3A). Pre-
treatment of whole blood samples with a FcR blocking reagent (Miltenyi Biotec) almost 
completely displaced IgG antibodies from the neutrophil surface, suggesting that neutrophils 
bind IgG in a FcγR-dependent mode and not through the recognition of neutrophil surface 
antigens by the Fab portion of IgG antibodies. Consistent with these observations, we found 
that serum concentrations of ICs were significantly higher in severe COVID-19 patients 
compared with healthy donors (Figure 3A, right panel). We then analyzed whether sera 
from COVID-19 patients might be able to induce the activation of healthy neutrophils in a 
FcγR-dependent mode. Incubation of neutrophil isolated from healthy donors with sera from 
severe COVID-19 patients resulted not only in the binding of IgG ICs (Figure 3B), but also 
in the activation of the neutrophil respiratory burst (Figure 3C), being this response 



















To gain insight into the mechanisms underlying the activation of healthy neutrophils by sera 
from COVID 19 patients, we analyzed the impact of two variables: disease severity and titers 
of anti-SARS-CoV-2 IgG antibodies. Sera from severe and mild COVID-19 patients were 
titrated by an ELISA to detect anti-SARS-CoV-2 IgG antibodies (see Methods). In agreement 
with previous reports [23, 24], we observed that sera from severe patients showed higher 
antibody titers compared with mild patients (not shown). By screening a large number of 
sera, we could select a panel of sera with high (1:3200) and low-titers (<1:100) of IgG anti-
SARS-CoV-2-antibodies from either severe or mild patients, and analyzed their ability to 
activate the respiratory burst of healthy neutrophils. High titers of specific IgG antibodies 
were shown to be associated with a high ability to trigger the respiratory burst of neutrophils 
isolated from healthy donors. Interestingly, sera from severe patients show a higher ability to 
induce the activation of the neutrophil respiratory burst when compared with sera from mild 
patients with similar titers of anti-SARS-CoV-2 IgG ntibodies (Figure 4A).  
 
It has been shown that a decreased fucosylation of the Fc portion of IgG antibodies increases 
its affinity for FcγRIII [25]. Recent reports indicated that anti-SARS-CoV-2 IgG antibodies 
in severely ill COVID-19 patients show a unique ability to trigger FcγRIIIa-dependent 
inflammatory responses by macrophages due to a reduced fucosylation at the Fc portion of 
IgG [26]. We analyzed whether IgG antibodies directed to the SARS-CoV-2 spike protein 
from severe and mild COVID-19 patients differed in their ability to induce neutrophil 
activation. To this aim, all sera were adjusted to a final titer of 1:3200, and different sera 
dilutions were incubated with immobilized S protein for 1 h in 96 well plate flat bottom. 
Then, wells were washed and neutrophils isolated from healthy donors suspended in RPMI 
medium supplemented with 10% FCS were added, and plates were incubated for 30 min at 


















respiratory burst when serum dilutions of 1:10 and 1: 20 were used. Using sera at a final 
dilution of 1:20, neutrophil activation was analyzed by measuring respiratory burst activation, 
up-regulation of CD11b expression and CXCL8 production. No differences were observed 
between the responses induced by IgG antibodies from severe and mild COVID-19 patients 
regarding neutrophil respiratory burst activation, by contrast a higher CD11b expression and 
an increased stimulation of CXCL8 production was observed for neutrophils activated by IgG 
antibodies from severe patients (Figure 4 C and D left panel). We then performed a similar 
analysis using isolated monocytes. ICs failed to induce the production of TNF-α and IL6 (not 
shown), but efficiently induced the production of  CXCL8, being this response significantly 
higher for ICs prepared with IgG antibodies from severe patients (Figure 4D right panel). 
We conclude that ICs prepared with anti-SARS-CoV2 IgG antibodies from severe COVID-




Inflammation is a hallmark of severe COVID-19 but the players and the mechanisms 
involved in the onset and exacerbation of the inflammatory response remain poorly defined. 
It was assumed that SARS-CoV-2-induced lung dysfunction is associated with a strong storm 
of inflammatory cytokines but a rigorous comparison with other inflammatory syndromes 
such as sepsis, cytokine release syndrome, and acute respiratory distress revealed serum IL6 
concentrations among 10 to 100 fold lower in severe COVID-19 [27]. In contrast, various 
non-cytokine markers of inflammation and tissue injury such as D-dimer, C-reactive protein, 
ferritin, and lactate dehydrogenase (LDH) are increased in a similar fashion in severe-


















inflammation in severe COVID-19 could not be only attributed to the acquisition of an 
inflammatory signature by macrophages.  
 
High numbers of neutrophils have been found in the bronchoalveolar lavage fluid of patients 
with severe COVID-19 [8, 9, 28]. Elevated blood neutrophil counts have shown to predict 
worse outcomes in COVID-19 [29], while increased concentrations of neutrophils products 
such as neutrophil extracellular traps (NETs) [30], myeloperoxidase (MPO) , and calprotectin 
[31] have been described in patients with severe-COVID-19. A large body of evidence 
suggests that NETs play a major role in the pathogenesis of severe COVID-19. NETs 
components have been detected in the plasma of patients with severe COVID-19 and 
correlated with disease severity [11, 32, 33]. Moreover, NET-containing microthrombi with 
neutrophil-platelet infiltration has been described in pulmonary autopsies from patients died 
from COVID-19 [32], suggesting that NETs triggering immunothrombosis is involved in the 
pathogenesis of severe COVID-19. Neutrophils could also contribute to thrombotic events in 
the course of COVID-19 by releasing neutrophil-derived microparticles [33]. They have been 
associated to thrombosis in different diseases [34, 35] and have been found at high 
concentrations in the plasma of COVID-19 patients [33]. Interestingly, the activation of 
neutrophils and platelets in the course of COVID-19 could be induced not only by 
inflammatory mediators, but also directly by interacting with SARS-CoV-2 [30, 36, 37].  
 
We here show that neutrophils from severe COVID-19 patients, but not from patients with 
mild or moderate disease, display an activated phenotype and spontaneously produce CXCL8 
and CCL2. Production of CXCL8 correlated with the plasmatic concentrations of LDH and 
D-dimer, two recognized markers of disease severity [2, 18]. Consistent with previous reports 


















a correlation between the degree of neutrophil-platelet interaction and the days of 
hospitalization was found.  
 
Neutralizing IgG antibody titers have shown to be higher in severe COVID-19 compared 
with mild or moderate disease [23, 24], calling into question whether IgG antibodies might 
also be involved in the pathogenesis of COVID-19. No evidence has been published 
supporting a role for antibody-dependent enhancement of infection in COVID-19. However, 
IgG antibodies might contribute to disease severity not only by promoting viral infection, but 
also by inducing inflammatory responses. In fact, studies performed in SARS-CoV/macaque 
models showed that IgG antibodies against the SARS-CoV-2 spike protein increases the 
severity of lung injury by promoting an inflammatory response mediated by macrophages 
[39]. 
 
The drivers of inflammation in COVID-19 remain to be clarified. Little attention has been 
paid to the possible role of IgG ICs. However, different observations suggest that IgG ICs 
might in fact be involved in the pathogenesis of severe COVID-19: a) severe disease is 
associated with high levels of circulating anti-SARS-Cov-2 IgG antibodies [23, 24], b) viral 
antigens have been found in the blood of patients [40, 41], c) systemic complement activation 
occurs in the course of severe COVID-19 [42]; d) severe infection is associated to an 
exaggerated extrafollicular B cell response [43], and the production of a variety of 
autoantibodies directed to red blood cells [22], platelets [21], type-I interferons [20], self-
carbohydrates [44], self-phospholipids [45], antinuclear antibodies (ANAs), and anti‐
cytoplasmic neutrophil antibodies (ANCAs)[46]. Our present results suggest not only that 
IgG ICs promote neutrophil activation in the course of severe COVID-19 but also that ICs 


















associated with severe COVID-19. Interestingly, it has been recently reported that sera from 
severe COVID-19 patients contain ICs that activate platelets through FcγRIIA [47]. Our 
results also suggest that anti-SARS-IgG antibodies from severe patients express a unique pro-
inflammatory profile when incorporated into ICs. This observation is consistent with previous 
studies showing that ICs containing anti-spike IgG antibodies from severely ill COVID-19 
patients induce a hyper-inflammatory response mediated by monocytes, macrophages and 
NK cells, due to a reduced fucosylation of the Fc fragment of IgG antibodies directed to 
SARS-CoV-2, resulting in an enhanced affinity to FcγRIII [26, 48].  
 
A careful look of our experimental data reveal substantial heterogeneity among severely ill 
COVID-19 patients. Some of them show a dramatic increase in the neutrophil expression of 
CD11b and CD66b as well as in the spontaneous production of CXCL8 and CCL2, while 
other patients show values comparable to HD. This observation could reflect that severe 
COVID-19 could progress through different underlying mechanisms involving, or not, the 
participation of either neutrophils or ICs. Beyond this heterogeneity, our results suggest that 
ICs might contribute to the induction and maintenance of the inflammatory response in 
severe COVID-19 patients. Our observations suggest that the administration of Intravenous 
Immunoglobulin (IVIG) might represent a useful therapeutic tool to prevent disease 
progression. In fact, different reports have shown that IVIG treatment improves the course of 
severe COVID-19 [49]. The anti-inflammatory effects mediated by IVIG involve different 
mechanisms including the blockade of activating FcγRs, the induction of inhibitory signals 
through FcγRIIb, a decreased half-life of IgG autoantibodies due to the blockade of the 
neonatal receptor for IgG (FcRn), and the neutralization of inflammatory mediators such as 
cytokines and complement components [50]. All these mechanisms might contribute to 
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LEGENDS TO FIGURES 
 
Figure 1. Peripheral blood neutrophils from severe COVID-19 patients show an 
activated phenotype. (A-B) The expression of CD11b, CD66b, and CD62L by freshly 
isolated neutrophils from healthy donors (HD) or COVID-19 patients (mild, moderate or 
severe) was analyzed by flow cytometry. (C) Association of platelets with neutrophils was 
evaluated in freshly whole blood samples by flow cytometry by analyzing the presence of the 
platelet marker CD62-P (upper panels) or CD41 (lower panels) in the neutrophil gate. Lower 
right panel shows the correlation between the days of hospitalization and the degree of 
neutrophil-platelet association. (D) Neutrophils (2 × 10
6
/ml) were cultured for 10 h at 37°C. 
Percentages of apoptotic cells were then evaluated by staining with annexin-V 
FITC/propidium iodide and flow cytometry. Bars represent the mean ± SEM of n (4-16) 
donors. Histograms and dot-plots show representative experiments. One-way ANOVA was 
used for comparisons in A, B and D. Kruskal-wallis test was used in C. *P<0.05, **P<0.01, 
***P<0.001, and ****P<0.0001. 
 
Figure 2. Spontaneous production of CXCL8 by neutrophils from COVID-19 patients 
positively correlates with classical markers of disease severity.  
(A, left panel) Supernatants from unstimulated neutrophils (10 × 10
6
/ml) from HD or 
COVID-19 patients cultured at 37°C for 18 h were collected, and the presence of CXCL8 
was analyzed by ELISA. (A, center and right panel) Correlation between the spontaneous 
production of CXCL8 by neutrophils and plasmatic levels of LDH and D-dimer. (B) The 
expression of CXCR1 by freshly isolated neutrophils from HD or severe COVID-19 patients 
was analyzed by flow cytometry. (C) Supernatants from unstimulated neutrophils (10 × 
10
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presence of CCL2 was analyzed by ELISA. (D) Supernatants from unstimulated neutrophils 
(10 × 10
6
/ml) from HD (n=8) or severe COVID-19 patients (n=13) cultured at 37°C for 18 h 
were collected. A transwell migration assay was performed by placing healthy neutrophils 
(1.5 x 10
5
/100 l medium supplemented with 10% FCS) 
 
in the upper chamber and 
neutrophils supernatants (100 l), IL-8 (10 ng/ml) or culture medium (control) in the lower 
chamber. After 1 h of incubation at 37°C, cell migration was analyzed by flow cytometry, 
and the results expressed as the percentage of neutrophils that have migrated through de 
membrane. A representative experiment (n=3) is shown. (A-C) Bars represent the mean ± 
SEM of n (7-14) donors. Kruskal-wallis test was used in A and C. One-way ANOVA was 
used in D and unpaired t test was used in B. Histograms show representative experiments. 
*P<0.05, **P<0.01. 
 
Figure 3. IgG immune complexes may contribute to neutrophil activation in the course 
of severe COVID-19. 
(A) IgG binding to neutrophils was evaluated in freshly whole blood samples from HD or 
severe COVID-19 patients, by staining with a FITC-labeled antibody directed to human IgG. 
In some experiments, whole blood samples were treated with a FcR blocking reagent before 
staining.  Bars represent the MFI mean ± S.E. (n=4-12) after subtraction of the mean value of 
the isotype. Right panel shows the concentration of serum ICs from healthy donors (n = 30) 
and severe COVID-19 patients (n = 37), indicated as PEG index. (B) Isolated neutrophils 
(2x10
6
/ml) were incubated in culture medium supplemented with 10% serum from HD or 
severe COVID-19 patients for 1 h at 4°C. Then, cells were stained with a PE-labeled 
antibody directed to human IgG and analyzed by flow cytometry. A representative 
experiment (n=3) performed with sera from HD (n=5) or sera from severe COVID patients 
(n=8) is shown.  (C) Purified healthy neutrophils (2x10
6


















dihydrorhodamine-123 and incubated for 30 min at 37°C in medium supplemented with 10% 
of serum from HD or COVID-19 patients. Production of hydrogen peroxide was analyzed by 
flow cytometry. A representative experiment (n=3) performed with sera from HD (n=29) or 
sera from mild (n=8) or severe COVID patients (n=26) is shown.  (D) Neutrophils were pre-
treated, or not, with a blocking mAb directed to FcγRII (clone IV.3), and production of 
hydrogen peroxide induced by serum (10%) from severe COVID-19 patients (n=15) was 
analyzed as described in (C). A representative experiment (n=3) is shown. Kruskal-wallis test 
was used for comparisons in A center right bar panel and C; unpaired t test was used in B. 
Mann-Whitney test was used in A center left panel and right panel; and paired t test was used 
in D. Histograms and dot-plots show representative experiments. *P<0.05, **P<0.01, 
***P<0.001, and ****<0.0001. 
Figure 4.  Inflammatory IgG antibodies anti-SARS-CoV-2 in severe COVID-19 patients  
(A) A panel of sera with high (1:3200) and low-titers (<1:100) of IgG anti-SARS-CoV-2-
antibodies from either severe or mild COVID-19 patients was selected, as described in 
METHODS. Purified healthy neutrophils (2x10
6
/ml) were labelled with dihydrorhodamine-
123 and incubated for 30 min at 37°C in medium supplemented with 10% of serum from 
HDs or COVID-19 patients. Production of hydrogen peroxide was analyzed by flow 
cytometry as described above. A representative experiment (n=3) performed with sera from 
HD (n=24), or mild patients/low titers (n=23), mild patients/high titers (n=23), severe 
patients/low titers (n=24) and severe patients/high titers (n=24) is shown. (B-D) Sera from 
severe and mild COVID-19 patients containing high levels of IgG antibodies anti-SARS-
CoV-2 were tittered and adjusted to a final titer of 1:3200. Sera from HDs were used as 
controls. Different sera dilutions (B) or 5% of normalized sera (C-D) were incubated with 
immobilized SARS-CoV-2 antigens (trimer spike protein and RBD domain of spike protein) 




















healthy neutrophils (C and D left panel) or 1.x10
5 
healthy monocytes (D right 
panel) suspended in 100 µl of RPMI medium supplemented with 10% FCS were added, and 
the production of hydrogen peroxide by neutrophils (B and C left panel) and the expression 
of CD11b by neutrophils (C right panel) was evaluated after 30 min or 6 h of incubation, 
respectively. The production of CXCL8 by neutrophils (D left panel) and monocytes (D 
right panel) were evaluated after 6 and 18 h of incubation, respectively. A representative 
experiment (n=3) performed with sera (titer 1:3200) from mild patients (n=17-46) or severe 
patients (25-59) is shown in C-D. Bars represent the mean ± SEM. Kruskal-wallis test 
was used in A, C left bar panel and D. One-way ANOVA was used in C right panel. 



















     TABLE 1 
 








Demographic and clinical data 
Age, years, median (range) 42.8 ± 2.7 57.3 ± 6.6 63.4 ± 5.3 
Sex, male, n (%) 75.9 78.9 47.4 
Fever (%) 17.2 31.6 57.9 
ICU admission, n (%) 0 5.3 78.9 
Laboratory parameters (mean ± SEM)     
Leukocyte counts/mm3 6724 ± 616 7762 ± 616 8153 ± 2173 
Neutrophils counts/mm3 4306 ± 598   6055 ± 1506 6807 ± 2208 
Lymphocytes counts/mm3 1476 ± 162 1112 ± 192 514 ± 186 
Neutrophil to Lymphocyte ratio 2.84 ± 0.41 5.25 ± 1.07 8.00 ± 3.21 
Platelets/mm3 207524±15607 197786±23929 205545±14006 
LDH (U/L) 302.0 ± 13.1 384.9 ± 42.0 640.0 ± 142.2 
D-dimer (ng/ml) 403.1 ± 66.5 577.6 ± 179.5 1391.0 ± 269.1 
CRP (mg/L) 2.96 ± 0.67 4.84 ± 1.22 12.72 ± 2.57 
Ferritin (ng/ml) 405.6 ± 90.0 572.0 ± 136.6 1622.0 ± 485.2 
Comorbidities     
Hypertension (%) 6.9 21.0 26.3 
Obesity (%) 13.8 26.3 36.8 


















Stroke (%) 0 0 0 
Cardiovascular disease (%) 10.3 21.1 15.8 
Chronic obstructive Pulmonary disease 
(%) 
3.4 5.3 10.5 
Chronic kidney disease (%) 3.4 5.3 0 
Days of symptoms at admission 1.6 ± 0.4 1.9 ± 0.4 2.8 ± 0.7 
Blood sampling (days after diagnosis by 
PCR)  
5.8 ± 1.4   7.0 ± 1.7 11.2 ± 4.2         
Days of hospitalization  7.26 ± 0.4   13.5 ± 1.99 21.00 ± 2.9         
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